Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
This application claims priority under 35 USC .sctn. 119 to application Ser. Nos. 60/344,788, filed Jan. 7, 2002, and 60/383,575, filed May 29, 2002, the specifications of which are incorporated herein by reference in their entirety.
The present invention relates to retroviral protease inhibitors and, more particularly, relates to novel compounds, compositions and methods for inhibiting retroviral proteases. This invention, in particular, relates to resistance-repellent HIV protease inhibitors, compositions, and uses thereof for treating HIV infections, particularly infections caused by one or more species of drug resistant HIV strains.
